Syngenta Group, the Chinese-owned seed and pesticide giant, is once again postponing its application for a Hong Kong IPO, which aims to raise up to $10 billion. This marks another delay in the company's long-standing effort to go public. The Basel-based company, controlled by state-owned Sinochem, had previously withdrawn its Shanghai listing application in March 2024 after a process that spanned several years, hampered by China's economic slowdown and stricter IPO approval curbs on the mainland.
The company had aimed to launch its Hong Kong offering in the fourth quarter of 2026, contingent on market conditions. Syngenta plans for the IPO to potentially be one of the world's largest this year, with sources indicating it could sell up to 20% of its shares. The listing is partly driven by a desire to reduce Chinese ownership, which could alleviate U.S. concerns amid heightened trade tensions.
Syngenta has engaged several banks to manage the deal, including Chinese investment bank CICC and Goldman Sachs, with UBS Group AG and Bank of America Corp. also expected to play roles. The proceeds from the IPO are intended to reduce the company's net debt, which stood at $24.8 billion at the end of 2024, and fund research and development as well as acquisitions. Syngenta typically invests about $2 billion annually in R&D and seeks to expand its product pipeline.
